Safety and Tolerability of Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)
Recruiting
99 years and younger
All
Phase
N/A
9 participants needed
1 Location
Brief description of study
To evaluate the safety and tolerability of OPGx-001 administered via subretinal injection to one eye (treated eye) of participants with LCA5-IRD. The safety and tolerability as assessed by:
1. Number of dose limiting toxicity (DLT) events at the proposed doses
2. Number of procedure-related adverse events (AEs)
3. Number and severity of AEs related to OPGx-001
4. Change from baseline in total retinal thickness as assessed by optical coherence tomography (OCT) (changes in total retinal
thickness, outer retinal thickness, in microns) To assess the efficacy of a single subretinal injection of OPGx-001 (at three different doses) in the treated eye over 3 years in participants with LCA5-IRD.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 852708
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
